Mar. 19 at 5:02 PM
Barclays reiterated
$XERS Overweight;
$9, and said: Current Mkt Cap <
$1B Feels Punitive Given
$4B Peak Sales.
$CORT
Torrent Pharmaceuticals Limited/Somerset Therapeutics, LLC
$AMPH $ZLDPY $NVO TEVA
Barclays added:::LOE Concerns Feel Overblown With a breakout year in 2025 (shares +130%), XERS stock has been volatile in 2026 due primarily to
1) Recorlev LOE concerns and
2) macro volatility.
While we have less visibility into the macro, we think the LOE concerns are overblown and came away from our Miami conf with increased conviction.
